Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy

Cancer Letters

Volumn 302, Issue 1, 2011, Pages 63-68

  Chen, Yizuo ^a,d   Chen, Canming ^a,b   Yang, Benlong ^a,b   Xu, Qinghua ^a   Wu, Fei ^a   Liu, Fang ^a   Ye, Xun ^a   Meng, Xia ^c   Mougin, Bruno ^c   Liu, Guangyu ^a,b   Shen, Zhenzhou ^a,b   Shao, Zhimin ^a,b   Wu, Jiong ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c BIOMÉRIEUX   (France)

^d THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; ER; Gene expression profiling; Neoadjuvant chemotherapy; Prediction

Indexed keywords

CARBOPLATIN; ESTROGEN RECEPTOR; PACLITAXEL;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; DRUG RESPONSE; ESR1 GENE; FEMALE; GATA3 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TFF1 GENE; TFF3 GENE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 79251597030     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.12.014     Document Type: Article

References (17)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet 365 (2005) 1687-1717.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Polychemotherapy for early breast cancer: an overview of the randomised trials, Lancet 352 (1998) 930-942.
3. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 1999, 17:460-469.
4. Wolmark N., Wang J., Mamounas E. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 2001, 30:96-102.
5. Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 2006, 24:1037-1044.
6. von Minckwitz G., Raab G., Caputo A., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21days compared with doxorubicin and docetaxel every 14days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J. Clin. Oncol. 2005, 23:2676-2685.
7. Bear H.D., Anderson S., Brown A. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 2003, 21:4165-4174.
8. G.N. Hortobagyi, D.F. Hayes, L. Pusztai, Integrating newer science into breast cancer prognosis and treatment: a review of current molecular predictors and profiles, in: 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 2002, pp. 191-202 (May 18-21).
9. Thuerigen O., Schneeweiss A., Toedt G., et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 2006, 24:1839-1845.
10. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 2006, 24:4236-4244.
11. Gianni L., Zambetti M., Clark K. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 2005, 23:7265-7277.
12. Chen X.S., Nie X.Q., Chen C.M. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann. Oncol. 2010, 21:961-967.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.
14. Kaufmann M., Hortobagyi G.N., Goldhirsch A., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 2006, 24:1940-1949.
15. Kaufman M., Klinga K., Runnembaum M. In vitro adiamycin sensitivity test and hormonal receptors in primary breast cancer. Cancer 1980, 47:2797-2800.
16. Makris A., Powles T.J., Dowsett M. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res. 1997, 3:593-600.
17. Colleoni M., Orvieto E., Nole F. Prediction of response to primary chemotherapy for operable breast cancer. Eur. J. Cancer 1999, 35:574-579.